TEST:

VisioCyt®

P=N/A, N=190, Completed, Institut de Cancérologie de Lorraine | Trial completion date: Dec 2024 --> Jun 2025

P=N/A, N=700, Recruiting, Institut Paoli-Calmettes | Trial completion date: Nov 2024 --> Jun 2025 | Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2024 --> Jun 2025

These results demonstrate the value of combining clinical and biological information, especially to improve detection of low-grade bladder cancer. Some improvements will need to be made to the automatic extraction of clinical features to make the risk factor-based model more robust. However, as of now, the results support the assumption that this type of approach will be of benefit to patients.

P=N/A; Recruiting --> Completed

"VitaDX...announces the signing of a strategic partnership with Biogroup, one of the largest networks of medical biology laboratories in France, with more than 900 laboratories. This partnership aims to expand the number of locations for collecting urine samples from patients for the non-invasive VisioCyt® Bladder test – the first in vitro diagnostic test developed by VitaDX."

"Avero Diagnostics...and VitaDX International...are delighted to announce the signing of a strategic partnership aimed at deploying the VisioCyt® solution. Bladder throughout the United States...The VisioCyt® Bladder solution will be available in the United States early in the first quarter of 2025."

P=N/A; N=700; Not yet recruiting; Sponsor:Institut Paoli-Calmettes

P=N/A; Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Dec 2024

VisioCyt is a promising diagnostic tool for urothelial cancers with improved sensitivities for high-grade tumors and notably for low-grade tumors.

"Urinary biomarkers might have a complementary place in bladder cancer diagnosis and NMIBC surveillance. However, their clinical benefit remains to be confirmed."

"VitaDX...announces its collaboration with XPath to continue the deployment in France of its VisioCyt® solution for the early diagnosis of cervical cancer. the bladder, the 5th most common cancer in France, with more than 13,000 new cases per year...By fully integrating into the patient's care pathway and the logistics of pathological anatomy and cytology practices, the VisioCyt® solution makes it possible, from a simple urine sample, to obtain a rapid result while significantly improving diagnostic performance."

"VitaDX...announces its collaboration with MEDIPATH...to deploy VisioCyt®, a solution for the early diagnosis of bladder cancer, the 5th most common cancer in France...This tool allows an accelerated morphological analysis of all cells present on a digitized urine cytology, in a reliable and reproducible way...It relies on artificial intelligence (machine learning and deep learning) and image processing to facilitate the early detection of bladder cancer."